Bioclinica Predicts Demand for TQT Trials in China

Bioclinica Predicts Demand for TQT Trials in China
Bioclinica Predicts Demand for TQT Trials in China
Bioclinica has partnered with a Chinese hospital citing growing regulatory pressure for cardiac safety studies in the country as the key driver.

The US firm announced the ‘strategic partnership’ with TEDA International Cardiovascular Hospital (TICH) in Tianjin this week, claiming that the two organisations have already completed the first regulator-mandated Thorough QT (TQT) study in China.

The study - which was conducted in order to support an unnamed local drugmaker’s approval efforts - is likely to be the first of many in China according to Boaz Mendzelevski, MD, BioClinica's Vice President of Cardiology.

"The evolving regulatory environment in China will necessitate new safety standards and assessments of a similar nature for drugs in the pipeline, resulting in increased collaborative efforts and consultative input in support of Chinese pharmaceutical companies seeking domestic and global marketing approval for their new drugs​"

This was echoed by company director of operations in Asia, Onglee Weng, who said: “There is a substantial need for cardiac safety ​services in certified clinical facilities, and this partnership will make it easier for pharmaceutical sponsors to meet changing regulatory standards in the region​."

The new partnership follows just six months after Bioclinica was acquired by private equity firm JLL for $123m​ (€91m) and appears to be in keeping with CEO Mark Weinstein’s prediction that the takeover would help the contract services firm build “global scale​.”

CoreLab the firm that JLL bought and merged with Bioclinica in January, conducted the first regulatory-mandated TQT trial in Japan in 2010 in collaboration with Japanese partner Suzuken.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars